That reputation is true as far as its goes. But, in spite of the emphasis on pure science, Yeda Research and Development, Weizmann’s technology transfer arm, has had great success in its efforts to ...

An Israeli-Australian venture will use solar technology developed at the Weizmann Institute of Science ... license for the solar technology from Yeda, the Weizmann Institute's technology transfer ...

Yeda Research and Development Company, the Weizmann Institute’s technology transfer arm, has licensed the drug to Steba Biotech, which manufactures Tookad Soluble. Amir Naiberg, CEO of Yeda ...

Last year, Yeda Research and Development, the tech transfer office of the Weizmann Institute, sued ImClone and Sanofi-Aventis over the Erbitux patent. (The patent was owned by the latter and licensed ...

Yeda’s Chief Business Officer ... Johnson will encourage the growth of novel directions in research at the Weizmann Institute and the development of new intellectual property.” ...

Abbott Laboratories will fund research programs in select areas of medicine through Yeda Research and Development Company, the technology transfer arm of the world-renowned Weizmann Institute of ...

As a result, TxCell has exercised its option and signed an exclusive worldwide licensing agreement with Yeda Research and Development Co. Ltd., the technology transfer arm of the Weizmann Institute of ...

Yeda Research and Development Company, Weizmann’s technology transfer arm, has licensed the drug to Steba Biotech, which manufactures Tookad Soluble. Yeda CEO Amir Naiberg, said: “Our ...

Ronen Kreizman holds a Ph.D. in Nanoscience from the Weizmann Institute of Science and M.Sc. and B.Sc. in Materials Engineering, both from Ben-Gurion University of the Negev. Prior to joining YEDA R&D ...

The Weizmann Institute has been working with Steba researchers for some 20 years to develop Tookad, said Amir Naiberg, CEO of the Yeda Research and Development Company, the Weizmann Institute’s ...